Supplementary Table S1 A. Mean DAS28-CRP changes at 3, 6, and 12 months in patients with RA treated with baricitinib and proportion of patients achieving DAS28-CRP remission and LDA; patients are arrayed based on bDMARD-naïve *vs*. -IR and the concomitant use of MTX.

		Mean DAS28-CRP+SD				Remission (%)				LDA (%)			
		Basal (n=426)	3 m (n=314)	6 m (n=289)	12m (n=126)	Basal	3 m	6 m	12m	Basal	3 m	6 m	12 m
All patients		4.67 ± 1.05	3.10 ± 1.22**	2.78 ± 1.23**	2.31 ± 1.03**	13/426; 3.0%	114/314; 36.3%	149/289; 51.6%	81/126; 64.3%	22/426; 5.2%	62/314; 19.8%	46/289; 15.9%	21/126; 16.7%
bDMARD-naive	Total	4.68 ± 0.99	2.69 ± 1.11**^	2.25 ± 1.06**^	1.94 ± 0.83**^	1/144; 0.7%	55/114; 48.3%	77/110; 70.0%	49/62; 77.8%	7/144; 4.9%	25/114; 21.9%	16/110; 14.6%	9/62; 14.3%
	w/MTX	4.61 ± 0.97	2.59 ± 0.99**	2.29 ± 1.05**	1.94 ± 0.74**	0/85; 0%	36/73; 49.3%	44/65; 67.7%	31/39; 77.5%	6/85; 7.0%	16; 21.9%	9/65; 13.9%	6/39; 15.0%
	w/o MTX	4.78 ± 1.01	2.85 ± 1.28**	2.21 ± 1.08**	1.93 ± 0.97**	1/59; 1.7%	19/41; 46.3%	33/45; 73.3%	18/23; 78.3%	1/59; 1.7%	9; 22.0%	7/45; 15.6%	3/23; 13.0%
bDMARD-IR	Total	4.67 ± 1.08	3.34 ± 1.23**	3.10 ± 1.23**	2.68 ± 1.08**	12/282; 4.3%	59/200; 29.5%	72/179; 40.2%	32/64; 50.8%	15/282; 5.3%	37/200; 18.5%	30/179; 16.8%	12/64; 18.7%
	w/ MTX	4.79 ± 1.11	3.19 ± 1.18**	2.99 ± 1.19**	2.62 ± 0.96**	4/140; 2.9%	35/107; 32.7%	38/89; 42.7%	20/41; 48.8%	10/140; 7.1%	21/107; 19.6%	19/89; 21.4%	9/41; 21.9%
	w/o MTX	4.56 ± 1.05	3.51 ± 1.27**	3.21 ± 1.35**	2.77 ± 1.28**	8/142; 5.6%	24/93; 25.8%	34/90; 37.8%	12/23; 52.2%	5/142; 3.5%	16/93; 17.2%	11/90; 12.2%	3/23; 13.0%

Supplementary Table S1B. Proportion of patients achieving DAS28-CRP MDA and HDA; patients are arrayed based on bDMARD-naïve *vs*. -IR and the concomitant use of MTX.

		MDA (%)				HDA (%)			
		Basal	3 m	6 m	12m	Basal	3 m	6 m	12 m
All patients		251/426; 58.9%	116/314; 36.9%	79/289; 27.3%	23/126; 18.3%	140/426; 32.9%	22/314; 7.0%	15/289; 5.2%	1/126; 0.8%
bDMARD-naive	Total	86/144; 59.7%	32/114; 28.1%	13/110; 11.8%	5/62; 8.1%	50/144; 34.7%	2/114; 1.8%	4/110; 3.6%	0/62; 0%
	w/ MTX	50/85; 58.8%	21/73; 28.8%	10/65; 15.4%	3/39; 7.7%	29/85; 20.1%	0/73; 0%	2/65; 3.1%	0/39; 0%
	w/o MTX	36/59; 61.0%	11/41; 26.8%	3/45; 6.7%	2/23; 8.7%	21/59; 14.6%	2/41; 4.9%	2/45; 4.4%	0/23; 0%
bDMARD-IR	Total	165/282; 58.5%	84/200; 42.0%	66/179; 36.9%	18/64; 28.1%	90/282; 31.9%	20/200; 10.0%	11/179; 6.2%	1/64; 1.6
	w/ MTX	76/140; 54.3%	45/107; 42.1%	27/89; 30.3%	11/41; 26.8%	50/140; 35.7%	6/107; 5.6%	5/89; 5.6	0/41; 0%
	w/o MTX	89/142; 62.7%	39/93; 41.9%	39/90; 43.3%	7/23; 30.4%	40/142; 28.2%	14/93; 15.1%	6/90; 6.7%	1/23; 4.4%

RA: rheumatoid arthritis; bDMARDs: biological DMARDs; n: number; w/o: without; MTX: methotrexate; w: with; IR: insufficient response; m: months; DAS28: disease activity score 28; R: remission; LDA: low disease activity. MDA: moderate disease activity; HAD: high disease activity. *p<0.01 *vs*. baseline; **p<0.0001 *vs*. baseline (Wilcoxon signed-rank test); ^ p<0.01 n. *vs*. IR (Mann-Whitney test).

Supplementary Table S2 A. Mean CDAI changes at 3, 6, and 12 months in patients with RA treated with baricitinib and proportion of patients achieving CDAI remission and LDA; patients are arrayed based on bDMARD-naïve *vs*. -IR and the concomitant use of MTX.

		Mean CDAI +SD				Remission (%)				LDA (%)			
		Basal (n=417)	3 m (n=309)	6 m (n=268)	12m (n=126)	Basal	3 m	6 m	12m	Basal	3 m	6 m	**12 m**
All patients		25.8 ± 11.1	12.0 ± 9.2**	9.1 ± 9.3**	6.2 ± 7.0**	1/417; 0.2%	37/309; 12.0%	67/268; 25.0%	49/126; 38.9%	29/417; 7.0%	123/309; 39.8%	119/268; 44.4%	54/126; 42.9%
bDMARD-naive	Total	25.4 ± 9.7	9.2 ± 8.1**^	6.1 ± 8.0**^	4.1 ± 5.0^	0/142; 0%	20/114; 17.5%	42/110; 38.2%	32/63; 50.8%	4/142; 2.8%	55/114; 48.3%	50/110; 45.5%	24/63; 38.1%
	w/ MTX	24.7 ± 9.2	2.59 ± 0.99**	2.29 ± 1.05**	1.94 ± 0.74**	0/84; 0%	13/73; 17.8%	23/65; 35.4%	21/40; 52.5%	1/84; 1.2%	35/73; 48.0%	31/65; 47.7%	15/40; 37.5%
	w/o MTX	26.4 ± 10.3	10.3 ± 10.6**	6.4 ± 9.6**	4.5 ± 5.9**	0/58; 0%	7/41; 17.1%	19/45; 42.2%	11/23; 47.8%	3/58; 5.2%	20/41; 48.8%	19/45; 42.2%	9/23; 39.1%
bDMARD-IR	Total	26.0 ± 11.8	13.7 ± 9.4**	11.1 ± 9.5**	8.3 ± 8.0**	1/275; 0.4%	17/195; 8.7%	25/158; 15.8%	17/63; 27.0%	25/275; 9.1%	68/195; 34.9%	69/158; 43.7%	30/63; 47.6%
	w/ MTX	26.9 ± 13.2	12.5 ± 9.0**	10.8 ± 8.5**	7.4 ± 6.2**	0/138; 0%	12/105; 11.4%	13/88; 14.8%	11/40; 27.5%	13/138; 9.4%	37/105; 35.2%	42/88; 47.7%	20/40; 50.0%
	w/o MTX	25.1 ± 10.2	15.1 ± 9.7**	11.6 ± 10.7**	9.9 ± 10.3**	1/137; 0.7%	5/90; 5.6%	12/70; 17.1%	6/23; 26.1%	12/137; 8.8%	31/90; 34.4%	27/70; 38.6%	10/23; 43.5%

Supplementary Table S2 B. Proportion of patients achieving CDAI MDA and HDA; patients are arrayed based on bDMARD-naïve *vs*. -IR and the concomitant use of MTX.

		MDA (%)				HDA (%)			
		Basal	3 m	6 m	12m	Basal	3 m	6 m	12 m
All patients		145/417; 34.8%	110/309; 35.6%	57/268; 21.3%	21/126; 16.7%	242/417; 58.0%	39/309; 12.6%	25/268; 9.3%	2/126; 1.6%
bDMARD-naive	Total	59/142; 41.6%	32/114; 28.1%	13/110; 11.8%	7/63; 11.1%	79/142; 55.6%	7/114; 6.1%	5/110; 4.5%	0/63; 0%
	w/ MTX	37/84; 44.0%	23/73; 31.5%	8/65; 12.3%	4/40; 10.0%	46/84; 54.8%	2/73; 2.7%	3/65; 4.6%	0/40; 0%
	w/o MTX	22/58; 37.9%	9/41; 21.9%	5/45; 11.1%	3/23; 13.0%	33/58; 56.9%	5/41; 12.2%	2/45; 4.4%	0/23; 0%
bDMARD-IR	Total	86/275; 31.3%	78/195; 40.0%	44/158; 27.9%	14/63; 22.2%	163/275; 59.3%	32/195; 16.4%	20/158; 12.7%	2/63; 3.2%
	w/ MTX	44/138; 31.9%	44/105; 41.9%	25/88; 28.4%	9/40; 22.5%	81/138; 58.7%	12/105; 11.4%	8/88; 9.1%	0/40; 0%
	w/o MTX	42/137; 30.7%	34/90; 37.8%	19/70; 27.1%	5/23; 21.7%	82/137; 59.9%	20/90; 22.2%	12/70; 17.1%	2/23; 8.7%

RA: Rheumatoid Arthritis; bDMARDs: biological DMARDs; n: number; w/o: without; MTX: methotrexate; w: with; IR: insufficient response; m: months; CDAI: Clinical Disease Activity Index; R: remission; LDA: Low disease activity; MDA: moderate disease activity; HAD: high disease activity.
* $p<0.01$ *vs*. baseline; ** $p<0.0001$ *vs*. baseline (Wilcoxon signed-rank test); ^ $p<0.01$ n. *vs*. IR (Mann-Whitney test).